Plain-English translation of NCT04485013 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called , which is designed to help your immune system fight cancer by blocking a protein that tumors use to hide from your body's defenses. Researchers want to see if works better when given alone or combined with other existing cancer treatments like or . The medication is being studied in patients with several types of advanced cancer, including colorectal cancer, head and neck cancer, and lung cancer.
Many patients with advanced cancers stop responding to standard treatments, leaving them with limited options. This medication may help by unlocking the immune system's natural ability to fight cancer cells, potentially offering new hope for people whose cancers have become resistant to other drugs.
You likely qualify if…
You likely don't qualify if…
If you join, you will receive the medication either alone or combined with other cancer drugs, depending on which study arm you are assigned to. You will have regular clinic visits to receive treatment, have blood tests, and be monitored for side effects and how well the medication is working. The trial will track how the medication affects your tumors and how your body handles it, with ongoing follow-up visits as long as you are benefiting from the treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States